Prime Medicine, Inc.
primemedicine.comWhat Do They Do?
Develops gene-editing medicines using its Prime Editing technology for patients with genetic diseases, including liver disorders, cystic fibrosis and blood disorders.
10-K for FY2025, filed Mar 3, 2026We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially…View ↗
Our lead program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by…View ↗
Our pipeline includes wholly owned in vivo programs targeting liver genetic diseases - Wilson Disease, AATD - as well as early-stage…View ↗
How Do They Make Money?
Partners pay under research collaboration and licensing agreements through upfront fees, expense reimbursements, option and milestone payments, and potentially royalties on licensed-product sales. The company earns revenue over the expected period of work under each agreement.
10-K for FY2025, filed Mar 3, 2026
$4.6M
-
10-K for FY2025, filed Mar 3, 2026
$4.6M ↗
Who Are Their Customers?
Research and licensing partners contract for rights to research, develop, manufacture and commercialize product candidates.
10-K for FY2025, filed Mar 3, 2026The Company enters into collaboration and licensing agreements with partners under which it may exclusively license rights to research…View ↗
Do Revenues Turn Into Profits?
No. It lost $201.1M in FY2025.
10-K for FY2025, filed Mar 3, 2026
−$208.4MView ↗
10-K for FY2025, filed Mar 3, 2026
−$201.1MView ↗
10-K for FY2025, filed Mar 3, 2026
−$167.1MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$42.1MView ↗
- ▼ −20% (Loss)
- vs −$52.6M in Q2 FY2025
-
Jul 8, 2026
Arbitration ruling confirms Prime’s rights to PM647
The tribunal ruled PM647 fell within Prime’s field under its agreement with Beam and denied Beam’s requests for damages and injunctive relief.
Sources
8-K, filed Jul 8, 2026
On July 6, 2026, Prime Medicine, Inc. (the "Company") received a final award (the "Final Award") from the arbitration tribunal (the…View ↗
-
Apr 16, 2026
Prime Medicine appoints a new chief financial officer
Svetlana Makhni was appointed chief financial officer and principal financial officer, effective April 16, 2026.
Sources
8-K, filed Apr 16, 2026
On April 7, 2026, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Svetlana Makhni as the Chief…View ↗
Portfolio focus
The earlier report described programs across blood, liver, eye and ear diseases and other indication groups; the latest centers internal development on in vivo liver editing, alongside cystic fibrosis and partnered ex vivo programs.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 3, 2026
Who Do They Compete With?
Competes with CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Caribou Biosciences, Beam, Verve Therapeutics, Tessera Therapeutics, Metagenomi Therapeutics, Scribe Therapeutics, Arbor Biotechnologies, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Wave Life Sciences, Moderna, Ultragenyx, Genetix Biotherapeutics, 4D Molecular Therapeutics, Vertex Pharmaceuticals, and Arrowhead Pharmaceuticals
10-K for FY2025, filed Mar 3, 2026The development of genetic medicines is highly competitive and rapidly evolving, with multiple companies pursuing therapeutic approaches…View ↗
Loading...
